focus -WSS

focus

author：fashion 2025-09-28 00:47:56 - browse：43732

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： A new ‘biological computer' targets cancer while sparing healthy cells

Wikipedia

WSS

Mystery swirls around US soldier who entered North Korea days ago, officials say

Telehealth startups are trying to fill the menopause care vacuum

Medical experts exlpore how to eliminate bias in clinical algorithms

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Eating disorder hotline's move to chatbot carried cost for volunteers

Telehealth startups are trying to fill the menopause care vacuum

hotspot

focus

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

How one medical school became remarkably diverse

Tuskegee Airman Raymond Cassagnol dies at 102

Medical records are filled with copy

US jobless claims fall again as labor market continues to flash strength

Alkermes shareholders re

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Anesthesiologist group: stop taking Ozempic before surgery

The stock market has soared this year, but will it last? Experts weigh in

leisure time

UnitedHealth wins $3.3 billion takeover of Amedisys

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

Extensive review finds private equity owners jack up cost of care

knowledge

hotspot

Wikipedia

knowledge